

# Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

<https://marketpublishers.com/r/G74BCE6610B8EN.html>

Date: April 2024

Pages: 193

Price: US\$ 4,250.00 (Single User License)

ID: G74BCE6610B8EN

## Abstracts

### Summary

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of *Francisella novicida*. Other such systems are thought to exist. CRISPR/Edits Medicin2 from the bacterium *Leptotrichia shahii* is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS

III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Celectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of CRISPR and CRISPR-Associated (Cas)

Genes, also provides the value of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global CRISPR and CRISPR-Associated (Cas) Genes company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

#### CRISPR and CRISPR-Associated (Cas) Genes segment by Company

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR therapeutics

Intellia therapeutics, Inc.

Collectis

Horizon Discovery Plc

Sigma Aldrich

Precision Biosciences

Genscript

Sangamo Biosciences Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

#### CRISPR and CRISPR-Associated (Cas) Genes segment by Type

Genome Editing

Genetic engineering

gRNA Database/Gene Librar

CRISPR Plasmid

Human Stem Cells

Genetically Modified Organisms/Crops

Cell Line Engineering

#### CRISPR and CRISPR-Associated (Cas) Genes segment by Application

Biotechnology Companies

Pharmaceutical Companies

Academic Institutes

Research and Development Institutes

## CRISPR and CRISPR-Associated (Cas) Genes segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

## Study Objectives

1. To analyze and research the global CRISPR and CRISPR-Associated (Cas) Genes status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CRISPR and CRISPR-Associated (Cas) Genes key companies, revenue, market share, and recent developments.
3. To split the CRISPR and CRISPR-Associated (Cas) Genes breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CRISPR and CRISPR-Associated (Cas) Genes market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CRISPR and CRISPR-Associated (Cas) Genes significant trends, drivers,

influence factors in global and regions.

6. To analyze CRISPR and CRISPR-Associated (Cas) Genes competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

### Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

### Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CRISPR and CRISPR-Associated (Cas) Genes industry.

Chapter 3: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.



## Contents

### **1 MARKET OVERVIEW**

- 1.1 Product Definition
- 1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, 2019 VS 2023 VS 2030
- 1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

### **2 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET DYNAMICS**

- 2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
- 2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
- 2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
- 2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints

### **3 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COMPANY**

- 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023
- 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2019-2024)
- 3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024
- 3.4 Global CRISPR and CRISPR-Associated (Cas) Genes Company Manufacturing Base & Headquarters
- 3.5 Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application
- 3.6 Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time
- 3.7 Market Competitive Analysis
  - 3.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
  - 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
  - 3.7.3 2023 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier
- 3.8 Mergers & Acquisitions, Expansion

## **4 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY TYPE**

### 4.1 CRISPR and CRISPR-Associated (Cas) Genes Type Introduction

- 4.1.1 Genome Editing
- 4.1.2 Genetic engineering
- 4.1.3 gRNA Database/Gene Librar
- 4.1.4 CRISPR Plasmid
- 4.1.5 Human Stem Cells
- 4.1.6 Genetically Modified Organisms/Crops
- 4.1.7 Cell Line Engineering

### 4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type

- 4.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030)
- 4.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2030)
- 4.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)

## **5 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY APPLICATION**

### 5.1 CRISPR and CRISPR-Associated (Cas) Genes Application Introduction

- 5.1.1 Biotechnology Companies
- 5.1.2 Pharmaceutical Companies
- 5.1.3 Academic Institutes
- 5.1.4 Research and Development Institutes

### 5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application

- 5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030)
- 5.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2030)
- 5.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)

## **6 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY REGION**

### 6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019 VS 2023 VS 2030

### 6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2030)

6.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019-2024

6.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030)

6.3 North America

6.3.1 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)

6.3.2 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030

6.4 Europe

6.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)

6.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030

6.5 Asia-Pacific

6.5.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)

6.5.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030

6.6 Latin America

6.6.1 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)

6.6.2 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030

6.7 Middle East & Africa

6.7.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)

6.7.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030

## **7 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COUNTRY**

7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030

7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2030)

7.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024)

7.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030)

## 7.3 USA

7.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## 7.4 Canada

7.4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## 7.5 Germany

7.5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## 7.6 France

7.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## 7.7 U.K.

7.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.7.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## 7.8 Italy

7.8.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.8.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by

Type, 2023 VS 2030

7.8.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.9 Netherlands

7.9.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.9.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.9.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.10 Nordic Countries

7.10.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.10.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.10.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.11 China

7.11.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.11.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.11.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.12 Japan

7.12.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.12.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.12.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.13 South Korea

7.13.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.13.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.13.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.14 Southeast Asia

7.14.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.14.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.14.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.15 India

7.15.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.15.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.15.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.16 Australia

7.16.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.16.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.16.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.17 Mexico

7.17.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.17.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.17.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.18 Brazil

7.18.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.18.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.18.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.19 Turkey

7.19.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.19.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.19.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.20 Saudi Arabia

7.20.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.20.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.20.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

7.21 UAE

7.21.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)

7.21.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030

7.21.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030

## **8 COMPANY PROFILES**

8.1 Thermo Fisher Scientific

8.1.1 Thermo Fisher Scientific Company Information

8.1.2 Thermo Fisher Scientific Business Overview

8.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.1.5 Thermo Fisher Scientific Recent Developments

8.2 Editas Medicine

8.2.1 Editas Medicine Company Information

8.2.2 Editas Medicine Business Overview

8.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.2.5 Editas Medicine Recent Developments

8.3 Caribou Biosciences

8.3.1 Caribou Biosciences Company Information

8.3.2 Caribou Biosciences Business Overview

8.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue

and Gross Margin (2019-2024)

8.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.3.5 Caribou Biosciences Recent Developments

8.4 CRISPR therapeutics

8.4.1 CRISPR therapeutics Company Information

8.4.2 CRISPR therapeutics Business Overview

8.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.4.5 CRISPR therapeutics Recent Developments

8.5 Intellia therapeutics, Inc.

8.5.1 Intellia therapeutics, Inc. Company Information

8.5.2 Intellia therapeutics, Inc. Business Overview

8.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.5.5 Intellia therapeutics, Inc. Recent Developments

8.6 Collectis

8.6.1 Collectis Company Information

8.6.2 Collectis Business Overview

8.6.3 Collectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.6.4 Collectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.6.5 Collectis Recent Developments

8.7 Horizon Discovery Plc

8.7.1 Horizon Discovery Plc Company Information

8.7.2 Horizon Discovery Plc Business Overview

8.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.7.5 Horizon Discovery Plc Recent Developments

8.8 Sigma Aldrich

8.8.1 Sigma Aldrich Company Information

8.8.2 Sigma Aldrich Business Overview

8.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and



## Gross Margin (2019-2024)

8.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.8.5 Sigma Aldrich Recent Developments

## 8.9 Precision Biosciences

8.9.1 Precision Biosciences Company Information

8.9.2 Precision Biosciences Business Overview

8.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.9.5 Precision Biosciences Recent Developments

## 8.10 Genscript

8.10.1 Genscript Company Information

8.10.2 Genscript Business Overview

8.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.10.5 Genscript Recent Developments

## 8.11 Sangamo Biosciences Inc.

8.11.1 Sangamo Biosciences Inc. Company Information

8.11.2 Sangamo Biosciences Inc. Business Overview

8.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.11.5 Sangamo Biosciences Inc. Recent Developments

## 8.12 Lonza Group Limited

8.12.1 Lonza Group Limited Company Information

8.12.2 Lonza Group Limited Business Overview

8.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.12.5 Lonza Group Limited Recent Developments

## 8.13 Integrated DNA Technologies

8.13.1 Integrated DNA Technologies Company Information

8.13.2 Integrated DNA Technologies Business Overview

8.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.13.5 Integrated DNA Technologies Recent Developments

8.14 New England Biolabs

8.14.1 New England Biolabs Company Information

8.14.2 New England Biolabs Business Overview

8.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.14.5 New England Biolabs Recent Developments

8.15 Origene Technologies

8.15.1 Origene Technologies Company Information

8.15.2 Origene Technologies Business Overview

8.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)

8.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

8.15.5 Origene Technologies Recent Developments

## **9 CONCLUDING INSIGHTS**

## **10 APPENDIX**

10.1 Reasons for Doing This Study

10.2 Research Methodology

10.3 Research Process

10.4 Authors List of This Report

10.5 Data Source

10.5.1 Secondary Sources

10.5.2 Primary Sources

## List Of Tables

### LIST OF TABLES

Table 1. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends

Table 2. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers

Table 3. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges

Table 4. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints

Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (US\$ Million) & (2019-2024)

Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Company (2019-2024)

Table 7. Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024 & (US\$ Million)

Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Key Company Manufacturing Base & Headquarters

Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application

Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time

Table 11. Global Company Market Concentration Ratio (CR5 and HHI)

Table 12. Global CRISPR and CRISPR-Associated (Cas) Genes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)

Table 13. Mergers & Acquisitions, Expansion

Table 14. Major Companies of Genome Editing

Table 15. Major Companies of Genetic engineering

Table 16. Major Companies of gRNA Database/Gene Librar

Table 17. Major Companies of CRISPR Plasmid

Table 18. Major Companies of Human Stem Cells

Table 19. Major Companies of Genetically Modified Organisms/Crops

Table 20. Major Companies of Cell Line Engineering

Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2024) & (US\$ Million)

Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2025-2030) & (US\$ Million)

Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by

Type (2019-2024)

Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2025-2030)

Table 26. Major Companies of Biotechnology Companies

Table 27. Major Companies of Pharmaceutical Companies

Table 28. Major Companies of Academic Institutes

Table 29. Major Companies of Research and Development Institutes

Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2024) & (US\$ Million)

Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2025-2030) & (US\$ Million)

Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2024)

Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2025-2030)

Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024) & (US\$ Million)

Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2019-2024)

Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030) & (US\$ Million)

Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2025-2030)

Table 40. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030 (US\$ Million)

Table 41. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024) & (US\$ Million)

Table 42. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2019-2024)

Table 43. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030) & (US\$ Million)

Table 44. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2025-2030)

Table 45. Thermo Fisher Scientific Company Information

Table 46. Thermo Fisher Scientific Business Overview

Table 47. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 48. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 49. Thermo Fisher Scientific Recent Development

Table 50. Editas Medicine Company Information

Table 51. Editas Medicine Business Overview

Table 52. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 53. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 54. Editas Medicine Recent Development

Table 55. Caribou Biosciences Company Information

Table 56. Caribou Biosciences Business Overview

Table 57. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 58. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 59. Caribou Biosciences Recent Development

Table 60. CRISPR therapeutics Company Information

Table 61. CRISPR therapeutics Business Overview

Table 62. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 63. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 64. CRISPR therapeutics Recent Development

Table 65. Intellia therapeutics, Inc. Company Information

Table 66. Intellia therapeutics, Inc. Business Overview

Table 67. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 68. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 69. Intellia therapeutics, Inc. Recent Development

Table 70. Cellectis Company Information

Table 71. Cellectis Business Overview

Table 72. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 73. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 74. Cellectis Recent Development

- Table 75. Horizon Discovery Plc Company Information
- Table 76. Horizon Discovery Plc Business Overview
- Table 77. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 78. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- Table 79. Horizon Discovery Plc Recent Development
- Table 80. Sigma Aldrich Company Information
- Table 81. Sigma Aldrich Business Overview
- Table 82. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 83. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- Table 84. Sigma Aldrich Recent Development
- Table 85. Precision Biosciences Company Information
- Table 86. Precision Biosciences Business Overview
- Table 87. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 88. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- Table 89. Precision Biosciences Recent Development
- Table 90. Genscript Company Information
- Table 91. Genscript Business Overview
- Table 92. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 93. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- Table 94. Genscript Recent Development
- Table 95. Sangamo Biosciences Inc. Company Information
- Table 96. Sangamo Biosciences Inc. Business Overview
- Table 97. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 98. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- Table 99. Sangamo Biosciences Inc. Recent Development
- Table 100. Lonza Group Limited Company Information
- Table 101. Lonza Group Limited Business Overview
- Table 102. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 103. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes

## Product Portfolio

Table 104. Lonza Group Limited Recent Development

Table 105. Integrated DNA Technologies Company Information

Table 106. Integrated DNA Technologies Business Overview

Table 107. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 108. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 109. Integrated DNA Technologies Recent Development

Table 110. New England Biolabs Company Information

Table 111. New England Biolabs Business Overview

Table 112. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 113. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 114. New England Biolabs Recent Development

Table 115. Origene Technologies Company Information

Table 116. Origene Technologies Business Overview

Table 117. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 118. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

Table 119. Origene Technologies Recent Development

Table 120. Research Programs/Design for This Report

Table 121. Authors List of This Report

Table 122. Secondary Sources

Table 123. Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture
- Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030) & (US\$ Million)
- Figure 4. Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023 (US\$ Million)
- Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US\$ Million)
- Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
- Figure 7. Genome Editing Picture
- Figure 8. Genetic engineering Picture
- Figure 9. gRNA Database/Gene Librar Picture
- Figure 10. CRISPR Plasmid Picture
- Figure 11. Human Stem Cells Picture
- Figure 12. Genetically Modified Organisms/Crops Picture
- Figure 13. Cell Line Engineering Picture
- Figure 14. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
- Figure 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)
- Figure 17. Biotechnology Companies Picture
- Figure 18. Pharmaceutical Companies Picture
- Figure 19. Academic Institutes Picture
- Figure 20. Research and Development Institutes Picture
- Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
- Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)
- Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)



Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region: 2019 VS 2023 VS 2030

Figure 26. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US\$ Million)

Figure 27. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030

Figure 28. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US\$ Million)

Figure 29. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030

Figure 30. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US\$ Million)

Figure 31. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030

Figure 32. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US\$ Million)

Figure 33. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US\$ Million)

Figure 35. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030

Figure 36. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 37. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 38. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 39. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 40. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 41. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 42. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 43. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 44. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share

by Application, 2023 VS 2030 & (%)

Figure 45. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 46. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 47. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 48. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 49. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 50. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)

Figure

## I would like to order

Product name: Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Product link: <https://marketpublishers.com/r/G74BCE6610B8EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G74BCE6610B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

